Menu
Recruiting NCT03351842

Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20%

Phase II Interventional Chemotherapy, Adjuvant Lung Adenocarcinoma, Stage I Treatment Histological Type of Neoplasm

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: cis Platinum/Carboplatin, Pemetrexed Disodium, Undergo surgery.
Who it may be relevant to
Registry conditions: Chemotherapy, Adjuvant, Lung Adenocarcinoma, Stage I, Treatment, Histological Type of Neoplasm. Basic parameters: 19 years — 70 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

A PHASE II STUDY Of ADJUVANT CHEMOTHERAPY After SURGERY For STAGE I Lung ADENOCARCINOMA PATIENTS With MICROPAPILLARY COMPONENT More Than Or EQUAL To 20%

Overview

Randomized phase II trial aims to compare surgery with or without adjuvant chemotherapy in treating patients who are pathologically diagnosed as stage I lung adenocarcinoma with micropapillary component no less than 20%.

Detailed description

The presence of micropapillary component in adenocarcinoma is a predictor of poor prognosis, and has been reported to be to be chemosensitive to platinum-based chemotherapy. Seeking a more appropriate treatment for these patients, we perform this randomized phase II clinical trial. About 460 stage I lung adenocarcinoma patients with micropapillary component ≥ 20% will be included and divided into two group. Patients in the control group will only undergo complete R0 resection of the lesion, no further therapy will be used. While patients in the experimental group are going to receive platinum-based chemotherapy (comprising cisplatin and pemetrexed disodium)about 1 month after therapeutic surgery. Treatment continues every 3 weeks for 4 courses. Clinic and telephone follow up will be conducted for survival data monitoring.

DFS(disease free survival rate) and OS(overall survival rate) curves will be calculated using the Kaplan-Meier, life-table method. Comparison of the survival curve for the two groups will be performed using the log-rank test.

Interventions

  • Drug cis Platinum/Carboplatin, Pemetrexed Disodium
    Intravenous inject Pemetrexed Disodium for Injection over 10 minutes, waiting for at least 30 minutes, then followed by cis Platinum/ Carboplatin over 2 hours
  • Procedure Undergo surgery
    Therapeutic conventional surgery, R0 resection

Primary outcome measures

  • Disease-Free-Survival-Rate [Time frame: up to 60 months]
Secondary outcome measures (3)
  • Overall-Survival-Rate [Time frame: up to 60 months]
  • Disease-Free-Survival-Time [Time frame: up to 60 months]
  • Overall-Survival-Time [Time frame: up to 60 months]

Eligibility criteria

Inclusion criteria

  • Completely resected Stage I NSCLC as defined by the International Staging System
  • Pathologically diagnosed Stage I micropapillary predominant lung adenocarcinoma
  • Patients must be randomized within 4 weeks from the date of surgery
  • No prior chemotherapy or radiation for non-small cell lung cancer
  • Performance status of 0 or 1
  • Women must be non-pregnant and non-lactating; patients of childbearing potential must agree to use an effective form of contraception while on study
  • Patients must have no history of previous or concomitant malignancy, other than curatively treated carcinoma in situ of the cervix, or basal cell or squamous cell carcinoma of the skin, or surgically treated in situ carcinoma of the breast, or other cancer for which the patient has been disease free for five years
  • Granulocytes >= 1,800/ul
  • Platelets >= 100,000/ul
  • Bilirubin < 1.5 mg/dl
  • SGOT(serum glutamic-oxaloacetic transaminase) (AST) < 2.0 x ULN(upper limit of normal value)

Exclusion criteria

  • Do not meet the inclusion criteria
  • There is evidence of distant metastases
  • Suffered from other malignancies in five years
  • Within the past January subjects received other drug trials
  • Having serious allergies or idiosyncratic persons, such as you can not use folic acid, dexamethasone, vitamin B12 patients
  • Severe lung or heart disease, a history
  • Refuses or is unable to sign informed consent to participate in trials
  • The abuse of drugs or alcohol addicts.
  • Patients with difficult to control bacterial, viral, fungal infections
  • Having a personality or mental disorders, without civil capacity or restricted civil capacity.
  • Being pregnant or lactating women.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

China · 1 center
  • Thoracic Surgery Department of Shanghai Pulmonary Hospital — Shanghai

Publications

  • Zhou Y, Bian D, Yang F, Xu X, Shen Y, Chen L, Dai J, Xu X, Zhu Y, Zhao D, Zhang P, Liu X, Jin K, Jiang G. Adjuvant chemotherapy for resected stage-ia lung adenocarcinoma with micropapillary histologic pattern. Interdiscip Cardiovasc Thorac Surg. 2026 Jun 9:ivag165. doi: 10.1093/icvts/ivag165. Online ahead of print. PMID 42266006

Identifiers

NCT: NCT03351842 · K17-151

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗